Biogen Inc.: Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS

In the Phase 3 VALOR study, the primary endpoint as measured by the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) did not reach statistical significance; however, signs of reduced

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,United States ,American ,Timothy Miller ,Walter Gilbert ,Charles Weissmann ,Heinz Schaller ,Alfred Sandrock Jr ,Ashleigh Koss ,Mike Hencke ,Kenneth Murray ,Head Of Research ,Linkedin ,Twitter ,Ionis Pharmaceuticals Inc ,Washington University School Of Medicine ,Nasdaq ,American Neurological Association ,Exchange Commission ,Youtube ,Facebook ,Media Snippet ,Washington University School ,Alfred Sandrock ,Open Label Extension ,Slow Vital Capacity ,Neurological Association ,Annual Meeting Presentation ,Ionis Pharmaceuticals ,Amyotrophic Lateral Sclerosis ,Nobel Prize ,Today Biogen ,Private Securities Litigation Reform Act ,Biogen ,Nnounces ,Topline ,Results ,Rom ,Ofersen ,Hase ,Study ,Pen ,Label ,Extension ,Sod1 ,